This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. PRN1008 (rilzabrutinib, Sanofi) is an oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor in a Ph. III trial for…
molecule
1 year ago ●
5 mins read
Context. INE963 (Novartis Institute for Tropical Diseases) is an oral, single dose, fast-acting blood-stage antimalarial candidate. The molecule was identified…
molecule
1 year ago ●
4 mins read
Context. MK-1454 (Merck) is an intratumoral stimulator of interferon (IFN) genes (STING) agonist that is being developed for treatment of…
molecule
1 year ago ●
3 mins read
Context. “Compound 24” (Amgen) is a kinesin-like protein 18A (KIF18A) inhibitor being developed for a subset of cancers with chromosomally…
molecule
1 year ago ●
4 mins read
Context. “Compound 10” (AstraZeneca) is an oral CDK5-mediated PPARγ phosphorylation inhibitor and partial PPARγ agonist being developed as an antidiabetic…
molecule
1 year ago ●
3 mins read
Context. Etavopivat (Forma Therapeutics) is an oral erythrocyte pyruvate kinase activator being developed for sickle cell disease and other hemoglobinopathies,…
molecule
1 year ago ●
3 mins read
Load More
